Meiji Yasuda Asset Management Co Ltd. Purchases 270 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Meiji Yasuda Asset Management Co Ltd. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,030 shares of the biopharmaceutical company’s stock after acquiring an additional 270 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Alnylam Pharmaceuticals were worth $493,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $26,000. Altitude Crest Partners Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $30,000. Robeco Institutional Asset Management B.V. increased its holdings in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares during the last quarter. Finally, V Square Quantitative Management LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $52,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Raymond James lifted their target price on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the company a “buy” rating in a report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Finally, Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $279.14.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The disclosure for this sale can be found here. Insiders have sold 103,148 shares of company stock valued at $25,658,824 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 0.9 %

Shares of Alnylam Pharmaceuticals stock opened at $273.88 on Friday. The company has a 50 day moving average of $260.11 and a 200-day moving average of $198.73. The company has a market cap of $34.64 billion, a PE ratio of -102.19 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same quarter in the previous year, the company earned ($2.21) earnings per share. The firm’s revenue for the quarter was up 107.0% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.